Metal Containing, E.g., Chromoproteins, Ferritin, Ferredoxins, Etc. Patents (Class 530/400)
  • Patent number: 5292869
    Abstract: The present invention relates to a method for isolating and purifying transferrin and lactoferrin receptor proteins from bacterial pathogens by affinity chromatography and to the preparation of vaccine antigens containing the purified receptor proteins.
    Type: Grant
    Filed: April 11, 1990
    Date of Patent: March 8, 1994
    Assignee: The Board of Governors of the University
    Inventor: Anthony B. Schryvers
  • Patent number: 5286848
    Abstract: A photoactive lanthanide complex of 2,2',2",9,9',9"-bis[nitrilotri(methylene)]tris(1,10-phenanthroline) and its functional derivative capable of bonding with substrate such as polymer and protein are provided. The lanthanide complex is usable for photosynthesis and photoimmunoassay.
    Type: Grant
    Filed: April 26, 1993
    Date of Patent: February 15, 1994
    Assignee: Hamamatsu Photonics K.K.
    Inventor: Katsu Honzawa
  • Patent number: 5284832
    Abstract: Iron complexes with conalbumin and its derivatives, such as acetylconalbumin and succinylconalbumin, with an iron content ranging from 2 to 30% by weight, useful for the treatment of sideropenic and hypochromic anaemia, preparation process and pharmaceutical compositions containing them as active ingredients.
    Type: Grant
    Filed: October 14, 1992
    Date of Patent: February 8, 1994
    Assignee: Mediolanum Farmaceutici S.p.A.
    Inventors: Gianni Ferrari, Pier G. Pagella, Oscar Baiardo
  • Patent number: 5277908
    Abstract: A method and compositions for reducing ischemic, inflammatory or septic injury in an animal that includes administration to the animal of an effective amount of a modified superoxide dismutase, wherein the modification comprises substituting a first amino acid residue located within 3-12 .ANG. of the active site of the superoxide dismutase with a second amino acid residue capable of reacting with a highly reactive nitrating species, such as nitronium ion, formed from the reaction of peroxynitrite and superoxide dismutase.
    Type: Grant
    Filed: May 29, 1992
    Date of Patent: January 11, 1994
    Assignee: The UAB Research Foundation
    Inventors: Joseph S. Beckman, Haralambos Ischiropoulos, Craig D. Smith
  • Patent number: 5273896
    Abstract: The transfer of a textile dye from a dyed fabric to another fabric during washing or rinsing is inhibited by adding an enzyme exhibiting peroxidase activity or an enzyme exhibiting a suitable oxidase activity to the wash liquor in which said fabrics are washed and/or rinsed. Peroxidase is produced extracellularly by some strains of Bacillus pumilus. The novel peroxidase preparation from B. pumilus is a microperoxidase, i.e. it contains hemopeptide as an active component. The preparation has improved stability at high temperature, at high pH and at high concentrations of hydrogen peroxide. It can be produced without undesired catalase activity.
    Type: Grant
    Filed: October 17, 1990
    Date of Patent: December 28, 1993
    Assignee: Novo Nordisk A/S
    Inventors: Gitte Pedersen, Bjorn E. Christensen, Palle Schneider
  • Patent number: 5272257
    Abstract: A method for preparing phycobiliprotein/amine-reactive dye conjugates is disclosed in which the conjugates so prepared overcome the energy transfer/fluorescent quenching dilemma encountered in the use of prior art conjugates. A phycobiliprotein, for example, phycoerythrin or allophycocyanin, is conjugated with an amine-reactive dye, for example, Texas Red or carboxyfluorescein succinimidyl ester, in the presence of a selective salt which causes a hydrophobic intramolecular rearrangement of the phycobiliprotein thereby exposing more hydrophobic sites for binding to the amine-reactive dye. The conjugates prepared according to the invention are useful in multiple color fluorescence assays without requiring the use of multiple exciting sources.
    Type: Grant
    Filed: September 3, 1992
    Date of Patent: December 21, 1993
    Assignee: Coulter Corporation
    Inventor: Ravinder K. Gupta
  • Patent number: 5258367
    Abstract: Method of using uteroferrin and rose for stimulating proliferation of hematopoietic cells.
    Type: Grant
    Filed: June 29, 1990
    Date of Patent: November 2, 1993
    Assignee: University of Florida
    Inventors: Fuller W. Bazer, Samuel Gross
  • Patent number: 5252715
    Abstract: A process for the preparation of an iron-free, pasteurized human transferrin is described and entails human transferrin being pasteurized in the presence of a complexing agent in solution, and the complexing agent being removed with the bound iron.This transferrin can be used as pharmaceutical or growth factor.
    Type: Grant
    Filed: December 11, 1991
    Date of Patent: October 12, 1993
    Assignee: Behringwerke Aktiengesellschaft
    Inventor: Heinz Haupt
  • Patent number: 5227470
    Abstract: A method for forming a proteoliposome comprises incorporating into a liposome a membrane protein combined with a carrier. Further, a method for preparing a giant proteoliposome, comprises freezing and thawing an alkali metal salt solution containing a membrane protein and a lipid, and subsequently dialyzing against a second salt solution or a buffer solution having a lower osmotic pressure than that of said alkali metal salt solution. Further, a method for forming a proteoliposome, comprises freezing and thawing an alkali metal salt solution containing a membrane protein combined with a carrier and a lipid.
    Type: Grant
    Filed: August 19, 1992
    Date of Patent: July 13, 1993
    Assignee: Canon Kabushiki Kaisha
    Inventors: Tsunehiro Kanno, Junji Ohyama, Masanori Sakuranaga, Hiroyoshi Kishi, Nobuko Yamamoto, Kinya Kato, Harumi Iwashita, Yasuko Tomida
  • Patent number: 5173425
    Abstract: This invention relates to a process for the enhancement of naphthalene dioxygenase activity in organisms that have been transformed with DNA encoding the expression of a multiple component naphthalene dioxygenase enzyme. Cells containing the naphthalene dioxygenase enzyme are capable of producing indigo when cultured in the presence of indole. The invention includes procedures to enhance naphthalene dioxygenase activity by transforming a host cell with a DNA sequence that encodes at least two ferredoxin polypeptides for each reductase polypeptide and iron-sulfur polypeptide, by growing transformed organisms in the presence of iron, or by transforming a host cell with a DNA sequence that encodes a ferredoxin analog.
    Type: Grant
    Filed: August 4, 1989
    Date of Patent: December 22, 1992
    Assignee: Amgen Inc.
    Inventors: Cuneyt M. Serdar, Douglas C. Murdock, Burt D. Ensley, Jr.
  • Patent number: 5171846
    Abstract: A method for preparing a phycobiliprotein-Texas Red conjugate which overcomes the energy transfer/fluorescent quenching dilemma is disclosed. A phycobiliprotein, such as phycoerythrin, is conjugated with dye, such as Texas Red, in the presence of a selective salt which causes a hydrophobic intramolecular rearrangement of the phycobiliprotein thereby exposing more hydrophobic sites for binding to Texas Red. The conjugate is useful in multiple color fluorescence assays without requiring the use of multiple exciting sources.
    Type: Grant
    Filed: May 21, 1990
    Date of Patent: December 15, 1992
    Assignee: Coulter Corporation
    Inventor: Ravinder K. Gupta
  • Patent number: 5151412
    Abstract: Pharmaceutically active conjugates comprising a pharmaceutically active substance for treating a disorder of the body that involves a specified body tissue conjugated directly or indirectly with at least one fragment of an adhesive glycoprotein such as fibronectin, the said glycoprotein fragment(s) having improved binding specificity compared with the parent protein for the said body tissue.
    Type: Grant
    Filed: July 21, 1989
    Date of Patent: September 29, 1992
    Assignee: Central Blood Laboratories Authority
    Inventor: Robert A. Brown
  • Patent number: 5141743
    Abstract: The present invention relates to a method for isolating and purifying transferrin and lactoferrin receptor proteins from bacterial pathogens by affinity chromatography and to vaccine antigens containing the purified receptor proteins.
    Type: Grant
    Filed: January 10, 1991
    Date of Patent: August 25, 1992
    Assignee: University Technologies International, Inc.
    Inventor: Anthony B. Schryvers
  • Patent number: 5116953
    Abstract: An aqueous lactoferrin solution can be thermally treated for heat pasteurization or spray drying purposes substantially without impairing the iron-binding ability of the lactoferrin by first adjusting the ionic strength thereof in accordance with the formulae, wherein I is ionic strength and T is temperature (.degree.C.):log I.ltoreq.-T/10+5 (60.ltoreq.T.ltoreq.80.degree. C.)log I.ltoreq.-3 (T.gtoreq.80.degree. C.).
    Type: Grant
    Filed: October 17, 1989
    Date of Patent: May 26, 1992
    Assignee: Snow Brand Milk Products Co., Ltd.
    Inventors: Shunichi Dosako, Rika Shinooka, Maki Tanaka
  • Patent number: 5079149
    Abstract: The invention relates to a process for the preparation of purple membrane containing bacteriorhodopsin, which process comprises obtaining, in a manner know per se, the cell membrane from halobacteria cells, and subjecting the material to gel filtration chromatography in order to isolate the purple membrane from the cell membrane.
    Type: Grant
    Filed: April 17, 1990
    Date of Patent: January 7, 1992
    Assignee: Industrie GmbH
    Inventors: Stefan Neumann, Horst Leigeber
  • Patent number: 5073630
    Abstract: The invention relates to a polymeric anhydride of magnesium and proteic ammonium phospholinoleate having the following distribution of components expressed in percentage of magnesium (20.1.+-.0.9%), Ammonium (10.0.+-.3.3%), Phosphate (45.2.+-.2.7%), linoleic acid (11.6.+-.4.3%), total protein (0.49.+-.0.07%) with the presence in percentage of the following aminoacids: Aspartic Acid (7.19%), Threonine (3.56%), Serine (7.56%), Glutamic Acid (8.53%), Proline (0.5%), Glycine (9.69%), Alanine (7.46%), Valine (1.0%), Methionine (4.38%), Isoleucine (2.54%), Leucine (3.03%), Thyrosine (0.5%), Phenylanine (1.0%), Histidine (2.83%), Lysine (3.56%), Tryptofan (1.3%) and Arginine (35.2%).This compound is produced from a selected line of Aspergillus sp in culture of oat schaff and bouillon at the temperature of 30.degree./35.degree. C., pH 3-4 with low aeration (10 l/m) and agitation (40 rph) restricted to the first 48 hours of the producing process.
    Type: Grant
    Filed: May 23, 1990
    Date of Patent: December 17, 1991
    Assignee: Nunes & Duran Pesquisa Comercio e Desenvolvimento Ltda.
    Inventors: Odilon D. Nunes, Nelson E. C. Duran
  • Patent number: 5043101
    Abstract: This invention provides particle compositions possessing ferromagnetic, paramagnetic or diamagnetic properties. The particles are especially useful when used in the disease diagnostic and treatment regimens as described in U.S. Pat. Nos. 4,106,448, 4,136,683 and 4,303,636.
    Type: Grant
    Filed: March 29, 1988
    Date of Patent: August 27, 1991
    Inventor: Robert T. Gordon
  • Patent number: 5008388
    Abstract: The present invention relates to a method for the preparation of a new, physiologically active, water-soluble complex compound, hemin arginate or hemin lysinate. According to the invention crystalline hemin and one of the amino acids L-arginine or L-lysine, in a molar proportion of 1:3, are allowed to react at room temperature under vigorous stirring for 10 to 15 hours in a solvent mixture of acetone and water in a ratio of 300:20 v/v. The hemin arginate or hemin lysinate thus formed is a powdery, stable compound suitable for use as raw material in tablets or capsules or as dry substance for preparation of injections for treatment of various types of anemia, including iron deficiency anemia and anemias and diseases associated with defects in heme synthesis.
    Type: Grant
    Filed: December 2, 1985
    Date of Patent: April 16, 1991
    Assignee: Huhtamaki Oy
    Inventors: Grels D. Ingberg, Ritva L. A. Penttila, Reino O. Tokola, Raimo Tenhunen
  • Patent number: 4997914
    Abstract: A method for separating and purifying lactoferrin from milk is disclosed, which method comprises the steps of bringing raw milk containing lactoferrin into contact with a sulfuric ester of a crosslinked polysaccharide so that lactoferrin may be adsorbed by the sulfuric ester, and then eluting the adsorbed lactoferrin. The elution of the adsorbed lactoferrin is preferably conducted by the use of a buffer solution containing a 0.4-1.5 M aqueous sodium chloride solution.
    Type: Grant
    Filed: November 9, 1988
    Date of Patent: March 5, 1991
    Assignee: Snow Brand Milk Products Co., Ltd.
    Inventors: Hiroshi Kawakami, Morimasa Tanimoto, Shunichi Dousako
  • Patent number: 4985404
    Abstract: Prolonged parenteral release of a bioactive polypeptide at desirably effective levels can be achieved using novel compositions in which the polypeptide is present in a biocompatible oil in an unusually high proportion such as at least about 10% by weight. Also disclosed are certain metal-associated somatotropins that are useful for prolonged parenteral release of such somatotropins.
    Type: Grant
    Filed: June 29, 1988
    Date of Patent: January 15, 1991
    Assignee: Monsanto Company
    Inventor: James W. Mitchell
  • Patent number: 4950591
    Abstract: A channel protein has a Na.sup.+ /K.sup.+ selectivity of approximately 100 and capable of affecting Na.sup.+ membrane transport. Amiloride derivatives, and amiloride gel materials incorporating such derivatives, are useful in treating membrane transport, cellular volume and cellular pressure disorders and in isolating the channel protein. The channel protein is used in diagnostic assays and screening assays.
    Type: Grant
    Filed: August 14, 1987
    Date of Patent: August 21, 1990
    Inventor: Bruce D. Cherksey
  • Patent number: 4946944
    Abstract: Process for the selective extraction of metalloproteins from whey, by adsorption on a porous inorganic support in the form of particles, followed by elution of the metalloproteins thus absorbed by means of solutions, characterized in that the walls of the said particles are coated with a layer of aminated polysaccharides possessing acidic functional groups at the surface.
    Type: Grant
    Filed: August 21, 1989
    Date of Patent: August 7, 1990
    Assignees: Entremont S.A., National Elf Aquitane
    Inventors: Jacques Frankinet, Andree Peyrouset, Francois Spring
  • Patent number: 4939092
    Abstract: Iron proteinaceous derivatives, obtained from ferric or ferrous salts and lysozyme with glutaric or 1,2-cyclohexanedicarboxylic anhydride and their pharmaceutical use in the oral treatment of iron-deficiency anemia, are described.
    Type: Grant
    Filed: October 27, 1988
    Date of Patent: July 3, 1990
    Assignee: Unibois S.p.A.
    Inventors: Flavio Villani, Adriano Zamboni
  • Patent number: 4895807
    Abstract: A channel protein has a molecular weight of approximately 280 kD and is capable of affecting K.sup.+ and Cl.sup.- membrane transport. Furosemide and quinine derivatives, and polysaccharide or monosaccharide gels incorporating such derivatives, are useful in treating membrane transport, cellular volume and cellular pressure disorders and in producing the channel protein. The channel protein is used in diagnostic assays and screening assays is described.
    Type: Grant
    Filed: December 31, 1986
    Date of Patent: January 23, 1990
    Inventor: Bruce D. Cherksey
  • Patent number: 4830847
    Abstract: Diphosphonate-derivatized macromolecules, such as proteins, suitable for use as technetium-99m-based scanning agents and as anticalcification agents are disclosed. The scanning agents are prepared by combining Tc-99m in a +3, +4 and/or +5 oxidation state with the diphosphonate-derivatized macromolecules. Also disclosed are pharmaceutical compositions containing these diphosphonate-derivatized macromolecules and methods for scintigraphic imaging using these diphosphonate-derivatized macromolecules labeled with Tc-99m.
    Type: Grant
    Filed: June 28, 1985
    Date of Patent: May 16, 1989
    Assignee: The Procter & Gamble Company
    Inventors: James J. Benedict, Charles R. Degenhardt, James W. Poser
  • Patent number: 4746730
    Abstract: Bio-available iron-protein derivatives having an iron content of from 2% to 20% by weight and a nitrogen content of from 12% to 16% by weight obtained by reacting acetylated globin with an iron compound selected from the group consisting of ferric chloride, iron fructate and iron saccharate, and pharmaceutical compositions for treating and preventing iron deficiency in animals and humans.
    Type: Grant
    Filed: July 17, 1987
    Date of Patent: May 24, 1988
    Assignee: Mediolanum Farmaceutici
    Inventors: Luigi De Ambrosi, Piergiuseppe Pagella
  • Patent number: 4735796
    Abstract: This invention provides particle compositions possessing ferromagnetic, paramagnetic or diamagnetic properties. The particles are especially useful when used in the disease diagnostic and treatment regimens as described in U.S. Pat. Nos. 4,106,448, 4,136,683 and 4,303,636.
    Type: Grant
    Filed: May 7, 1985
    Date of Patent: April 5, 1988
    Inventor: Robert T. Gordon
  • Patent number: 4732974
    Abstract: A conjugate of a protein or polypeptide and a metal ion is prepared by reacting a metal ion transfer complex comprising a chelate of 4,5-dihydroxyl-m-benzenedisulfonic acid or a salt thereof with a protein or polypeptide that is covalently bound to an exogenous chelating group having a greater affinity than 4,5-dihydroxyl-m-benzenedisulfonic acid for the metal ion.
    Type: Grant
    Filed: March 5, 1986
    Date of Patent: March 22, 1988
    Assignee: Mallinckrodt, Inc.
    Inventors: Robert A. Nicolotti, Alan R. Ketring, Koon Y. Pak
  • Patent number: 4732864
    Abstract: Conjugates of target-seeking biologically active molecules and metallothionein in which all or part of the metal in the metallothionein is suitable for diagnostic or therapeutic applications.
    Type: Grant
    Filed: October 6, 1983
    Date of Patent: March 22, 1988
    Assignee: E. I. Du Pont de Nemours and Company
    Inventor: Glen L. Tolman
  • Patent number: 4681761
    Abstract: The major iron-regulated protein of a pathogenic species of the genus Neisseria, the gonococcal congener of which (MIRP) protein has a molecular weight of approximately 37,000 daltons and consisting of about 340 amino acids, is isolated in an immunospecific antigenically substantially pure form suitable for use as a vaccine against the pathogenic species of the genus Neisseria effective to stimulate the production of a protective level of antibodies to the pathogenic species in a susceptible host, by the steps of:growing cells of that pathogenic species in an iron-depleted bacteriologic media;harvesting the thus-grown cells;disrupting the cells;separating the soluble portion of the cells from the insoluble portion; andselectivity solubilizing the MIRP from the insoluble portion of the disrupted cells with an aqueous cationic surfactant aqueous media, e.g., cetyltrimethylammonium bromide; andremoving residual contaminates in the MIRP fraction by chromatographic fractionation.
    Type: Grant
    Filed: October 24, 1985
    Date of Patent: July 21, 1987
    Assignee: State of Oregon, acting by and through the Oregon State Board of Higher Education, acting for and on behalf of the Oregon Health Sciences University
    Inventors: Timothy A. Mietzner, Stephen A. Morse